GlassScriptPhysician profile
James Richard White
NPI 1093001315
$10,616.81
in general payments reported to CMS, 2019-2025
23 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,935 · 2020: $2,535 · 2021: $525 · 2022: $462 · 2023: $530 · 2024: $196 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wound Management Technologies, INC | $5,386.75 | 2019 | |
| Aerin Medical INC. | $2,488.32 | 2019-2024 | |
| Optinose US, INC. | $730.37 | 2019-2025 | |
| Medtronic, INC. | $579.25 | 2021-2023 | Propel |
| Regeneron Healthcare Solutions, INC. | $291.57 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $213.77 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $200.13 | 2023-2025 | Inspire |
| Advanced Bionics, LLC | $150.66 | 2019-2020 | |
| Intersect Ent, INC. | $113.78 | 2019-2020 | |
| Acclarent, INC | $71.70 | 2019-2023 | Acclarent Aera |
| Stryker Corporation | $62.93 | 2019-2022 | |
| Genzyme Corporation | $57.64 | 2021-2024 | |
| Ethicon US, LLC | $46.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.82 | 2019 | |
| Integra Lifesciences Corporation | $31.20 | 2024-2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $29.15 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic USA, INC. | $23.11 | 2019 | |
| Merck Sharp & Dohme LLC | $22.82 | 2025 | Keytruda |
| Cochlear Americas | $18.10 | 2019 | |
| Sanara Medtech INC. | $17.76 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.43 | 2019 | |
| Oyster Point Pharma, INC. | $13.54 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.